Results 161 to 170 of about 1,960,750 (298)

The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR‐TKIs treatment

British Journal of Clinical Pharmacology, EarlyView.
Background Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) have substantially improved outcomes in non‐small cell lung cancer (NSCLC); however, the development of treatment resistance remains a major clinical challenge. This study examines the association between concomitant prescriptions of H1‐antihistamines (H1AHs) and ...
Van Thuan Nguyen, Ngoc Hoang Le, Nhu Quynh Phan, Toan Trung Duong, Le Thi Anh Thu, Hsuan‐Chia Yang, Chih‐Wei Huang, Min‐Huei Hsu, Jason C. Hsu, Chien‐Tien Su, Phung‐Anh Nguyen   +10 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

New Insights Into Immunomodulatory Strategies for Drug Hypersensitivity Reactions: An EAACI Task Force Report. [PDF]

Clin Transl Allergy
Copaescu AM, Gueli V, Chahuan J, Albalawi W, Sfriso G, Giovannini M, de Las Vecillas L, Karavelia A, Labella M, Fernandez-Santamaria R, Mori F, Garvey LH, Bonadonna P, Torres MJ.   +13 more
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

JAK inhibition may prevent drug hypersensitivity reactions. [PDF]

JCI Insight
Hua X, Shah PN, Velasquez GA, Sidky L, Romar GA, Boer LW, Hickerson N, Cui TQ, Repetto F, Waldman A, Liang MG, Marcoux JP, Sellars M, Barrera V, Schmidt BA, Mostaghimi A, Foreman RK, Lian CG, Divito SJ.   +18 more
europepmc   +1 more source

Cofactors of drug hypersensitivity-A monocenter retrospective analysis. [PDF]

Front Allergy, 2022
Kühl J, Bergh B, Laudes M, Szymczak S, Heine G.   +4 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Clinical and behavioral determinants in pediatric non-immediate drug hypersensitivity: Low confirmation but persistent avoidance. [PDF]

Pediatr Allergy Immunol
Can Bostan O, Soyer O, Papadopoulos M, Tsabouri S.   +3 more
europepmc   +1 more source

Tailoring drug‐to‐lipid ratio in redox‐responsive lipid‐mimetic prodrug liposomes for superior cabazitaxel delivery and antitumor efficacy

BMEMat, EarlyView.
Redox‐responsive lipid‐mimetic prodrug liposomes with high drug‐to‐lipid ratios enhance cabazitaxel delivery, prolong circulation, and enable tumor‐selective drug release for superior antitumor efficacy and safety. Abstract Liposomes represent one of the most extensively investigated nanocarriers in drug delivery.
Shengyao Xu, Danping Wang, Si Zheng, Zhiyu Kuang, Ya Gao, Haiyu Zhao, Lurong Zhang, Jiayu Guo, Jingyi Zhang, Weiyao Li, Anhua Wang, Hongrui Lei, Zhonggui He, Ken‐ichiro Kamei, Jianzhao Niu, Lingyun Ma, Bingjun Sun   +16 more
wiley   +1 more source

Suspected upadacitinib-associated drug hypersensitivity mimicking disease exacerbation in ulcerative colitis. [PDF]

Clin J Gastroenterol
Madarame A, Kanda R, Shimizu Y, Itoi T.
europepmc   +1 more source